

# DISCLOSURE

## of Relevant Financial Relationships to Learners

**Rocky Mountain Inflammatory Bowel Disease**  
**March 13-15, 2026 Sun Valley, ID**

| Name                      | Ineligible Company  | Relationship   |
|---------------------------|---|--|
| Edward Barnes, MD         | AbbVie*, Boomerang, Pfizer*, J&J*,<br>Sanofi*, Takeda, Target RWE &<br>Pharmassetx<br>Eli Lilly                                     | Consultant<br><br>Research Support /Consultant   |
| Benjamin Click, MD        | AbbVie*   | Consultant   |
| Angelina Collins, MSN     | Abivax, Eli Lilly, Takeda and J&J<br>Cristcot   | Consultant/Advisor/Speaker<br>Advisor  |
| Rachel Conklin, MMS, PA-C | J&J<br>Everlywell   | Speaker<br>Employee  |
| Anne Flynn, MD            | AbbVie*   | Consultant   |
| Dana Lukin, MD            | AbbVie<br>Altrubio, Palatin Technologies,<br>Prime & PSI<br>Boehringer Ingelheim<br>Johnson & Johnson<br>Pfizer & Takeda<br>Vedanta | Consultant/Speaker<br>Consultant<br><br>Research Support /Consultant<br>Research Support /Advisor/Speaker<br>Consultant/Advisor<br>Advisor |
| Alexis Oonk, NP           | J&J*  | Advisor  |
| John Valentine, MD        | Abivax, Vedanta Biosciences,<br>Genetech/Roche & J&J, and Takeda  | Research Support   |

*\*relationship has ended*

All of the relevant financial relationships listed for these individuals have been mitigated.  
All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies.

### Definitions

An **ineligible company** is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

**Relevant financial relationships** are financial relationships of any amount occurring in the past 24 months with ineligible companies if the educational content an individual can control is related to the business lines or products of the ineligible company.